GBT takes a page from HIV playbook as it embarks on Oxbryta launch

The sickle cell disease market and patient support around the disease are both in the nascent stages. But Global Blood Therapeutics, a pioneer in the field with recently approved Oxbryta, sees an example to emulate as it embarks on its first launch: HIV.